ArticleAsian journal of transfusion science
Thromboelastographic insights into hemostatic alterations in coronavirus disease 2019 (COVID-19) patients.
Article in Asian journal of transfusion science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe coronavirus disease 2019 (COVID-19) has been shown to be a systemic disease affecting different organs of the body including hemostatic system. We aimed to see the utility of thromboelastography (TEG), a global viscoelastic test, in assessing hemostatic profile in COVID-19 patients.
methodsLaboratory records and relevant clinical profiles of our hospitalized COVID-19 patients who underwent TEG testing over a 1-year period were retrospectively studied.
resultsOut of 103 patients analyzed hypercoagulability was observed on TEG in 49 (48%) patients which was due to hyperfibrinogenemia with hypofibrinolysis and it persisted till 32-56 days in a subset of recovered patients. Patients with hypercoagulable profile had higher clotting index (CI), maximum amplitude (MA), α-angle and lower
conclusionThe present study confirmed significant hypercoagulability on TEG in almost half of the patients with COVID-19 despite anticoagulant therapy which was not detectable by conventional coagulation tests. It is plausible that the initial presentation for most of COVID-19 patients was that of hypercoagulable profile which eventually progressed to a hypocoagulable profile in a subset of patients with poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.